Replies to post #2148 on RespireRx Pharmaceuticals Inc (RSPI)

[jerrydylan]

this might also explain why we don't dose with memantine, and didn't do the petscan metabolic trial where it was disallowed. This may explain why the deal was done in AD anyway, reguardless of the ADHD results. I remember Neuro saying in his contact with Mark Varner the conversation suggested that a deal would take place likely in mid-07, (my take) about the time a response from the FDA would be in hand on the current tox study. It's possible , a small pipe would cover us into this, also why Stoll wants to do one AD trial next more proof of principle on metabolic function. Speaking of Nobel prizes , I read a biography of Arvid Carlsson of Nobel fame and Cotrex Scientific advisor, the question could be asked why he would transfer his knowledge and reputation to anything he didn't see as groundbreaking. Oh well , hoping for an uptick today........thanks again for your help on this subject.

[jerrydylan]

I have to agree with Neuro here as well, it would seem the iron is hot as COR seems like a wounded animal and more likely to agree to a large deal with Lilly or whomever, if the plan is not in place as my last post. Looking at RNAI as an example the grab bag of valuable IP may disipate over the next year to the point where you are going to need to make your stand now relative to where you see yourself in 5 years. I don't see these guys just cherrypicking the better late stage products as they have done for the past 5 years-PFE the most glaring example.